Empowering Precision Medicine: The Impact of 3D Printing on Personalized Therapeutic

AAPS PharmSciTech, Год журнала: 2023, Номер 24(8)

Опубликована: Ноя. 14, 2023

Abstract This review explores recent advancements and applications of 3D printing in healthcare, with a focus on personalized medicine, tissue engineering, medical device production. It also assesses economic, environmental, ethical considerations. In our the literature, we employed comprehensive search strategy, utilizing well-known databases like PubMed Google Scholar. Our chosen keywords encompassed essential topics, including printing, nanotechnology, related areas. We first screened article titles abstracts then conducted detailed examination selected articles without imposing any date limitations. The for inclusion, comprising research studies, clinical investigations, expert opinions, underwent meticulous quality assessment. methodology ensured incorporation high-quality sources, contributing to robust exploration role realm healthcare. highlights printing's potential customized drug delivery systems, patient-specific implants, prosthetics, biofabrication organs. These innovations have significantly improved patient outcomes. Integration nanotechnology has enhanced precision biocompatibility. demonstrates cost-effectiveness sustainability through optimized material usage recycling. healthcare sector witnessed remarkable progress promoting patient-centric approach. From implants radiation shielding offers tailored solutions. Its transformative applications, coupled economic viability sustainability, revolutionize Addressing biocompatibility, standardization, concerns is responsible adoption. Graphical

Язык: Английский

---

TROP2-directed nanobody-drug conjugate elicited potent antitumor effect in pancreatic cancer

Journal of Nanobiotechnology, Год журнала: 2023, Номер 21(1)

Опубликована: Ноя. 6, 2023

Pancreatic cancer is a highly aggressive malignancy with limited treatment options and poor prognosis. Trophoblast cell surface antigen 2 (TROP2), overexpressed in the tumors of more than half pancreatic patients, has been identified as potential target for antibody-drug conjugates (ADCs). Almost all reported TROP2-targeted ADCs are IgG type have poorly studied cancer. Here, we aimed to develop novel nanobody-drug conjugate (NDC) targeting TROP2 cancer.In this study, developed NDC, HuNbTROP2-HSA-MMAE, TROP2-positive HuNbTROP2-HSA-MMAE characterized by use nanobodies against human serum albumin (HSA) drug-antibody ratio 1. exhibited specific binding was internalized into tumor cells high endocytosis efficiency within 5 h, followed intracellular translocation lysosomes release MMAE induce apoptosis through caspase-3/9 pathway. In xenograft model cancer, doses 0.2 mg/kg 1 demonstrated significant antitumor effects, dose even eradicated tumor.HuNbTROP2-HSA-MMAE desirable affinity, internalization activity. It holds promise therapeutic option

Язык: Английский

---

Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis

Acta Pharmaceutica Sinica B, Год журнала: 2023, Номер 13(11), С. 4417 - 4441

Опубликована: Май 26, 2023

Rheumatoid arthritis is a chronic, systemic autoimmune disease predominantly based on joint lesions with an extremely high disability and deformity rate. Several drugs have been used for the treatment of rheumatoid arthritis, but their use limited by suboptimal bioavailability, serious adverse effects, nonnegligible first-pass effects. In contrast, transdermal drug delivery systems (TDDSs) can avoid these drawbacks improve patient compliance, making them promising option (RA). Of course, TDDSs also face unique challenges, as physiological barrier skin makes somewhat limited. To overcome this maximize efficiency, evolved in terms principle facilitation technology, different generations derived, which significantly improved efficiency even achieved individualized controlled delivery. review, we summarize systems, corresponding strategies, applications RA.

Язык: Английский

---

Postsurgical wound management and prevention of triple-negative breast cancer recurrence with a pryoptosis-inducing, photopolymerizable hydrogel

Journal of Controlled Release, Год журнала: 2023, Номер 356, С. 205 - 218

Опубликована: Март 8, 2023

Язык: Английский

---

Targeting triple negative breast cancer stem cells using nanocarriers

Discover Nano, Год журнала: 2024, Номер 19(1)

Опубликована: Март 7, 2024

Abstract Breast cancer is a complex and heterogeneous disease, encompassing various subtypes characterized by distinct molecular features, clinical behaviors, treatment responses. Categorization of based on the presence or absence estrogen receptor (ER), progesterone (PR), human epidermal growth factor 2 (HER2), leading to such as luminal A, B, HER2-positive, triple-negative breast (TNBC). TNBC, comprising around 20% all cancers, lacks expression ER, PR, HER2 receptors, rendering it unresponsive targeted therapies presenting significant challenges in treatment. TNBC associated with aggressive behavior, high rates recurrence, resistance chemotherapy. Tumor initiation, progression, are attributed stem cells (BCSCs), which possess self-renewal, differentiation, tumorigenic potential. Surface markers, self-renewal pathways (Notch, Wnt, Hedgehog signaling), apoptotic protein (Bcl-2), angiogenesis inhibition (VEGF inhibitors), immune modulation (cytokines, checkpoint inhibitors) among key targets discussed this review. However, targeting BCSC subpopulation presents challenges, including off-target effects, low solubility, bioavailability anti-BCSC agents. Nanoparticle-based offer promising approach target cellular processes implicated survival BSCS TNBC. In review, we explore nanocarrier-based approaches for BCSCs aiming overcome these improve outcomes patients. These nanoparticle-based therapeutic strategies hold promise addressing gap delivering while minimizing systemic toxicity enhancing efficacy. Graphical abstract

Язык: Английский

---

In Situ Sprayed Nanovaccine Suppressing Exosomal PD-L1 by Golgi Apparatus Disorganization for Postsurgical Melanoma Immunotherapy

ACS Nano, Год журнала: 2023, Номер 17(11), С. 10637 - 10650

Опубликована: Май 22, 2023

The anti-PD-L1 immunotherapy has shown promise in treating cancer. However, certain patients with metastatic cancer have low response and high relapse rates. A main reason is systemic immunosuppression caused by exosomal PD-L1, which can circulate the body inhibit T cell functions. Here, we show that Golgi apparatus-Pd-l1–/– exosome hybrid membrane coated nanoparticles (GENPs) significantly reduce secretion of PD-L1. GENPs accumulate tumors through homotypic targeting effectively deliver retinoic acid, inducing disorganization apparatus a sequence intracellular events including alteration endoplasmic reticulum (ER)-to-Golgi trafficking subsequent ER stress, finally disrupts PD-L1 production release exosomes. Furthermore, could mimic exosomes to access draining lymph nodes. antigen PD-l1–/– on activate cells vaccine-like effect, strongly promoting immune responses. By combining treatment sprayable situ hydrogel, successfully realized recurrence rate substantially extended survival periods mice models incomplete melanoma resection.

Язык: Английский

---

Alendronate Triggered Dual‐Cascade Targeting Prodrug Nanoparticles for Enhanced Tumor Penetration and STING Activation of Osteosarcoma

Advanced Functional Materials, Год журнала: 2023, Номер 33(49)

Опубликована: Сен. 3, 2023

Abstract The complex physiological environment in bone tissue poses a challenge to the efficient delivery of chemotherapeutic agents for osteosarcoma (OS) treatment; hence, an drug system designed OS is highly desired. Herein, alendronate (Ale)‐based cationic platinum prodrug nanoparticles (Ale NP) are developed, which exhibit cascade responsiveness tumor microenvironment. With Ale triggered targeting and charge reversal effects, NP demonstrates superior capacity achieving deep penetration into dense tissues. Furthermore, can induce dendritic cell (DC) maturation via activation cyclic GMP‐AMP synthase‐stimulator interferon genes (cGAS‐STING) pathway using drugs. potent phenanthridine (Pt(II)) be released presence overexpressed glutathione (GSH) cells, thereby dual‐targeted drugs OS. Notably, not only effectively eliminates internal region but also acts as STING agonist reverse suppressive microenvironment Overall, Ale‐triggered dual‐cascade significantly improve OS, hence paving promising avenue clinical treatment

Язык: Английский

---

Carbon Dots as Advanced Drug-Delivery Nanoplatforms for Antiinflammatory, Antibacterial, and Anticancer Applications: A Review

ACS Applied Nano Materials, Год журнала: 2023, Номер 6(11), С. 9071 - 9084

Опубликована: Май 19, 2023

Carbon dots (CDs), as rapidly developing nanomaterials, give new prospects for the treatment of various diseases. Their great biocompatibility and wide specific surface area make CDs excellent drug-delivery vehicles because they improve cellular uptake absorption allow medications to bind more easily. offer enormous potential delivery systems antiinflammatory medications. The activities drugs delivered by are higher than those free drugs. They also have controlled release, thus enhancing cumulative effect at inflammation site improving pharmacokinetics. Compared with small-molecule antibacterial medicines, CD-based efficacies, better targeting, increased internalization efficiency, decreased systemic side effects. benefits using anticancer drug carriers include high loading, lower dosage, regulated synergistic photothermal therapy, which offers a novel approach diagnosis cancer in clinical settings. However, it is important consider biosafety, toxicity, impact on immune system an organism before them therapy. This review discusses use antiinflammatory, antibacterial, summarizes current advantages challenges delivery.

Язык: Английский

---

Recent advances on nanostructured biomaterials in osteosarcoma treatment

Coordination Chemistry Reviews, Год журнала: 2023, Номер 493, С. 215315 - 215315

Опубликована: Июнь 24, 2023

Язык: Английский

---

The Significant Role of microRNAs in Gliomas Angiogenesis: A Particular Focus on Molecular Mechanisms and Opportunities for Clinical Application

Cellular and Molecular Neurobiology, Год журнала: 2023, Номер 43(7), С. 3277 - 3299

Опубликована: Июль 6, 2023

Язык: Английский

---